Your browser doesn't support javascript.
loading
Inhibition of PI3Kß signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Hancox, Urs; Cosulich, Sabina; Hanson, Lyndsey; Trigwell, Cath; Lenaghan, Carol; Ellston, Rebecca; Dry, Hannah; Crafter, Claire; Barlaam, Bernard; Fitzek, Martina; Smith, Paul D; Ogilvie, Donald; D'Cruz, Celina; Castriotta, Lillian; Wedge, Stephen R; Ward, Lara; Powell, Steve; Lawson, Mandy; Davies, Barry R; Harrington, Elizabeth A; Foster, Emily; Cumberbatch, Marie; Green, Stephen; Barry, Simon T.
Afiliação
  • Hancox U; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Cosulich S; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Hanson L; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Trigwell C; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Lenaghan C; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Ellston R; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Dry H; Oncology iMED Gatehouse Park, Waltham, Massachusetts.
  • Crafter C; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Barlaam B; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Fitzek M; Discovery Sciences AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Smith PD; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Ogilvie D; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • D'Cruz C; Oncology iMED Gatehouse Park, Waltham, Massachusetts.
  • Castriotta L; Oncology iMED Gatehouse Park, Waltham, Massachusetts.
  • Wedge SR; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Ward L; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Powell S; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Lawson M; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Davies BR; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Harrington EA; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Foster E; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Cumberbatch M; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Green S; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Barry ST; Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom. Simon.T.Barry@astrazeneca.com.
Mol Cancer Ther ; 14(1): 48-58, 2015 Jan.
Article em En | MEDLINE | ID: mdl-25398829

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Transdução de Sinais / Cromonas / Taxoides / Neoplasias de Mama Triplo Negativas / Inibidores de Fosfoinositídeo-3 Quinase / Compostos de Anilina / Antineoplásicos Idioma: En Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Transdução de Sinais / Cromonas / Taxoides / Neoplasias de Mama Triplo Negativas / Inibidores de Fosfoinositídeo-3 Quinase / Compostos de Anilina / Antineoplásicos Idioma: En Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Reino Unido